The high immunity LUSC group was enriched in several cancer-associated pathways such as NF-κB, PI3K–Akt, and RAS signaling pathways and immune signatures related to the establishment of lymphocyte and T-cell polarity. The gene discussed is NFKB1; the disease is cancer.